Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 8758623, 7 pages
https://doi.org/10.1155/2017/8758623
Research Article

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma

1Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 3rd Floor, W-350, 1760 Haygood Drive, Atlanta, GA 30322, USA
2Department of Pathology, Emory University, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA 30322, USA
3Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 4th Floor, W-440-B, 1760 Haygood Drive, Atlanta, GA 30322, USA
4Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
5Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA 30322, USA
6Department of Pediatrics, Vanderbilt University, Monroe Carell Jr. Children’s Hospital at Vanderbilt, 2220 Pierce Avenue, 396c Preston Research Building, Nashville, TN 37232, USA
7Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 4th Floor, W-470, 1760 Haygood Drive, Atlanta, GA 30322, USA

Correspondence should be addressed to Thomas Cash; gro.aohc@hsac.samoht

Received 23 September 2016; Revised 12 December 2016; Accepted 29 December 2016; Published 26 January 2017

Academic Editor: Dae-Geun Jeon

Copyright © 2017 Thomas Cash et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Arpin, M. Algrain, and D. Louvard, “Membrane-actin microfilament connections: an increasing diversity of players related to band 4.1,” Current Opinion in Cell Biology, vol. 6, no. 1, pp. 136–141, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. K. L. Gould, A. Bretscher, F. S. Esch, and T. Hunter, “cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1,” EMBO Journal, vol. 8, no. 13, pp. 4133–4142, 1989. View at Google Scholar · View at Scopus
  3. S. Hiscox and W. G. Jiang, “Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/β-catenin,” Journal of Cell Science, vol. 112, no. 18, pp. 3081–3090, 1999. View at Google Scholar · View at Scopus
  4. J. Li, K. Wei, H. Yu, D. Jin, G. Wang, and B. Yu, “Prognostic value of ezrin in various cancers: a systematic review and updated meta-analysis,” Scientific Reports, vol. 5, p. 17903, 2015. View at Publisher · View at Google Scholar
  5. Y.-C. Chuan, D. Iglesias-Gato, L. Fernandez-Perez et al., “Ezrin mediates c-Myc actions in prostate cancer cell invasion,” Oncogene, vol. 29, no. 10, pp. 1531–1542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Khanna, X. Wan, S. Bose et al., “The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis,” Nature Medicine, vol. 10, no. 2, pp. 182–186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Krishnan, B. Bruce, S. Hewitt, D. Thomas, C. Khanna, and L. J. Helman, “Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway,” Clinical and Experimental Metastasis, vol. 23, no. 3-4, pp. 227–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Luciani, A. Molinari, F. Lozupone et al., “P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin,” Blood, vol. 99, no. 2, pp. 641–648, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Lugini, F. Lozupone, P. Matarrese et al., “Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin,” Laboratory Investigation, vol. 83, no. 11, pp. 1555–1567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. I. McClatchey, “Merlin and ERM proteins: unappreciated roles in cancer development?” Nature Reviews Cancer, vol. 3, no. 11, pp. 877–883, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Parlato, A. M. Giammarioli, M. Logozzi et al., “CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway,” EMBO Journal, vol. 19, no. 19, pp. 5123–5134, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Yu, J. Khan, C. Khanna, L. Helman, P. S. Meltzer, and G. Merlino, “Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators,” Nature Medicine, vol. 10, no. 2, pp. 175–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Carneiro, P.-O. Bendahl, M. Åkerman et al., “Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas,” Journal of Clinical Pathology, vol. 64, no. 8, pp. 689–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Gao, C. Zhang, Y. Feng et al., “Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma,” PLoS ONE, vol. 7, no. 11, Article ID e50710, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Kim, E. Shin, S. Hong et al., “Clinical value of ezrin expression in primary osteosarcoma,” Cancer Research and Treatment, vol. 41, no. 3, pp. 138–144, 2009. View at Publisher · View at Google Scholar
  16. M. Köbel, E. Gradhand, K. Zeng et al., “Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma,” International Journal of Gynecological Pathology, vol. 25, no. 2, pp. 121–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Köbel, T. Langhammer, S. Hüttelmaier et al., “Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas,” Modern Pathology, vol. 19, no. 4, pp. 581–587, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Kong, Y. Li, S. Liu et al., “High expression of ezrin predicts poor prognosis in uterine cervical cancer,” BMC Cancer, vol. 13, article no. 520, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. H. W. Lee, E. H. Kim, and M.-H. Oh, “Clinicopathologic implication of ezrin expression in non-small cell lung cancer,” Korean Journal of Pathology, vol. 46, no. 5, pp. 470–477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Madan, M. Brandwein-Gensler, N. F. Schlecht et al., “Differential tissue and subcellular expression of ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic significance for head and neck squamous cell carcinoma,” Head and Neck, vol. 28, no. 11, pp. 1018–1027, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Mao, X.-R. Yuan, S.-S. Xu, X.-C. Jiang, and X.-T. Zhao, “Expression and functional significance of ezrin in human brain astrocytoma,” Cell Biochemistry and Biophysics, vol. 67, no. 3, pp. 1507–1511, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. E. H. Soule, W. Newton Jr., T. E. Moon, and M. Tefft, “Extraskeletal Ewing's sarcoma. A preliminary review of 26 cases encountered in the intergroup rhabdomyosarcoma study,” Cancer, vol. 42, no. 1, pp. 259–264, 1978. View at Publisher · View at Google Scholar · View at Scopus
  23. Y.-C. Wei, C.-F. Li, S.-C. Yu et al., “Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location,” Modern Pathology, vol. 22, no. 10, pp. 1351–1360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. W.-H. Weng, J. Åhlén, K. Åström, W.-O. Lui, and C. Larsson, “Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas,” Clinical Cancer Research, vol. 11, no. 17, pp. 6198–6204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Ferrari, L. Zanella, M. Alberghini, E. Palmerini, E. Staals, and P. Bacchini, “Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma,” Pediatric Blood and Cancer, vol. 50, no. 4, pp. 752–756, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. D.-H. Zhao, J. Zhu, W.-B. Wang et al., “Correlations of ezrin expression with pathological characteristics and prognosis of osteosarcoma: a meta-analysis,” Scientific World Journal, vol. 2014, Article ID 837543, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. I. MacHado, S. Navarro, F. Giner, M. Alberghini, F. Bertoni, and A. Llombart-Bosch, “Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors,” Virchows Archiv, vol. 457, no. 1, pp. 87–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. K. S. Samkoe, K. M. Tichauer, J. R. Gunn, W. A. Wells, T. Hasan, and B. W. Pogue, “Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach,” Cancer Research, vol. 74, no. 24, pp. 7465–7474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Bretscher, K. Edwards, and R. G. Fehon, “ERM proteins and merlin: integrators at the cell cortex,” Nature Reviews Molecular Cell Biology, vol. 3, no. 8, pp. 586–599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Cash, H. Yin, C. McCracken et al., “Prognostic impact of ezrin expression in Ewing sarcoma,” Journal of Clinical Oncology, vol. 34, no. supplement, abstrat 10545, 2016. View at Google Scholar